PMID: 9550795Apr 29, 1998Paper

Treatment of elderly patients with acute myeloid leukemia

Nederlands tijdschrift voor geneeskunde
B Löwenberg

Abstract

More than 50% of patients with acute myelogenous leukaemia are 60 years or older. Unlike the results of treatment of younger adults, the outcome in patients of higher age has been disappointing because intensive chemotherapy is tolerated less well, complications due to cardiac and pulmonary comorbidity occur sooner, toxicity due to reduced hepatic and renal function occurs earlier and older patients often present with leukaemia that is intrinsically of higher risk (e.g. unfavourable cytogenetics). Remission-induction therapy with an anthracycline derivative and cytarabine results in complete remission rates of approximately 50% in older patients; 15-20% of these remain free of leukaemia beyond 2-3 years and have a good quality of life. The clinical use of hematopoietic growth factors as adjuncts to chemotherapy to reduce complications and improve survival has not (yet) fulfilled his promise. By selecting older patients without major comorbidity for therapy and assessing the response to a first cycle of chemotherapy one may identify patients with the best response to treatment and avoid continued therapy in patients with poor prognosis. In this way the choice of treatment of the individual older patient can be optimized.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.